Abstract | Thousands of unique non-coding RNA (ncRNA) sequences exist within cells. Work from the past decade has altered our perception of ncRNAs from 'junk' transcriptional products to functional regulatory molecules that mediate cellular processes including chromatin remodelling, transcription, post-transcriptional modifications and signal transduction. The networks in which ncRNAs engage can influence numerous molecular targets to drive specific cell biological responses and fates. Consequently, ncRNAs act as key regulators of physiological programmes in developmental and disease contexts. Particularly relevant in cancer, ncRNAs have been identified as oncogenic drivers and tumour suppressors in every major cancer type. Thus, a deeper understanding of the complex networks of interactions that ncRNAs coordinate would provide a unique opportunity to design better therapeutic interventions.
. With few exceptions, research in the following years characterized RNAs mainly as intermediaries in the process of protein pro duction, principally as temporary copies of genetic information (mRNA), components of the ribosome (ribosomal RNAs (rRNAs)) or translators of codon sequence (tRNAs) 3 . For many years, proteins represented the primary functional end product of genetic informa tion, though the genes that encode them account for less than 2% of the genome.
The discovery of the first small temporal RNAs, lin eage defective 4 (lin-4) 4 and lethal 7 (let-7) 5 , identified 23 and 16 years ago, respectively, in Caenorhabditis elegans, demonstrated that some RNAs, despite lacking protein coding regions, are conserved functional molecules required for development. Since these early discoveries, studies have shown that functional products encoded by the genome are not limited to proteins but include a vari ety of unique RNAs 6, 7 . Advances in sequencing technolo gies have led to the discovery of a multitude of noncoding RNA (ncRNA) species, some highly conserved, such as microRNAs (mi RNAs), transcribed ultraconserved regions 6 and circular RNAs (circRNAs), and others gen erally lacking conservation across species, such as long ncRNAs (lncRNAs) 7 . Constituting almost 60% of the transcriptional output in human cells 8, 9 , ncRNAs have been shown to regulate cellular processes and pathways in developmental and pathological contexts.
It has become increasingly difficult to view ncRNA function in isolation. Some ncRNAs, like mi RNAs, target the mRNAs of many other different genes (and the mRNA of each gene can be targeted by multiple mi RNAs); thus, these ncRNAs naturally link associated genes into regulatory networks 10, 11 . To add more com plexity, mi RNAs also functionally interact with other species of ncRNAs, such as circRNAs and lncRNAs, to regulate their stability. In turn, lncRNAs and circRNAs regulate the abundance of available mi RNAs through mechanisms including sequestration. The highly com plex nature of some ncRNA interactions supports their roles as key regulators in important cellular programmes. Perturbations to these interactions have widespread con sequences affecting cell fate and are common in cancer. Though complex, the networks in which ncRNAs parti cipate are far from inscrutable. Many ncRNA interactions conform to characteristic patterns, or motifs, which are found in complex networks of all types, from biological to social 12, 13 . In this Review, we examine the nature of ncRNAs within cancer networks. We also highlight examples of ncRNAs participating in network motifs and other recur rent patterns of interactions and how these contribute to malignant phenotypes of cancer cells. Finally, we discuss some of the common disruptions to ncRNA interaction networks that are found in cancer. As RNAbased thera peutics have emerged in an increasing number of clini cal applications 14 , illuminating the complex networks of ncRNAs is fundamental to applying such technologies to cancer diagnosis and treatment.
ncRNAs in network motifs
As ncRNA genes represent a growing list of therapeutic targets in cancer 15 , the design of effective RNAbased anticancer strategies requires a much better under standing of the diverse and contextdependent nature of ncRNA interactions. The circuitous architecture of the molecular interactions that transduce signals in cells can be illuminated through the lens of network theory.
Networks are composed of nodes, the participatory members, and edges, the links or interactions between those members 12, 13 (FIG. 1a) . In this Review, we examine networks in which nodes are represented by products of genes, both noncoding and coding, connected through the interactions that occur between them to accom plish cellular functions. In all networks, the patterns in which the nodes connect determine not only the output of the system but also the robustness or vulnerability of that system to perturbations.
Biological networks have been shown to be scalefree and not random. In random networks, each node is con nected to other nodes through roughly the same number of connections. In scalefree networks, by contrast, no node is representative of all other nodes, as the number of connections varies for each node. Nodes with a high number of connections, such as mi RNAs and transcrip tion factors, represent network hubs. In most realworld scalefree networks, certain patterns of interactions are enriched in frequency. These recurring clusters of inter actions are known as network motifs. In this section, we examine the participation of ncRNAs in welldefined network motifs (FIG. 1a-c) . These patterns of interactions are common to all complex networks, from biological to social, and provide information about the structure of networks as well as their vulnerabilities 13 .
Feedback loops
In any complex system, mechanisms serve to protect the integrity of that system by adapting the system to vari ous inputs and by maintaining outputs within an appro priate range. One such mechanism found in complex networks is the feedback loop motif (FIG. 1b) . In cancer, some of these feedback loops can be coopted to pro mote tumori genesis rather than normal cell behaviour. Below we highlight some examples of ncRNA functions within feedback loops in cancer cells.
Throughout cell signalling networks, certain nodes function indirectly to promote their own expression. For example, a transcriptional target of the Hippo signalling pathway is the lncRNA lncARSR (a lncRNA activated in renal cell carcinoma (RCC) with sunitinib resistance). When the pathway is active its transcriptional effec tor, the transcriptional coactivator YAP1, translocates from the cytoplasm to the nucleus, where it engages with other transcription factors to initiate target gene transcription. Once expressed, the lncARSR transcript provides positive feedback (FIG. 1d) by binding to YAP1 at a site that sterically inhibits its phosphorylation by its negative regulator, the large tumour suppressor kinase 1 (LATS1) 16 . Phosphorylated YAP1 is unable to translocate into the nucleus. Thus, by binding to YAP1, lncARSR not only promotes its own expression 16 but also serves to lock Hippo pathway activity in a steady state, a com mon characteristic of positive feedback loops 13 . High expression of lncARSR has been associated with poor prognosis in patients with RCC, likely because lncARSR is required for the maintenance of tumourinitiating cells in renal tumours. The activity of lncARSR to promote the tumourinitiating abilities of renal cancer cells is dependent on YAP1 signalling, indicating that the posi tive feedback by lncARSR also promotes transcription of other oncogenic factors by YAP1 16 .
Feedforward loops ncRNAs frequently participate in another canonical net work motif, the feedforward loop, in which a node X simultaneously directly and indirectly regulates another node Z. The indirect regulation occurs through regu lation of a third node Y, which is regulated by X and regulates Z 13 (FIG. 1c) . A common example of this phe nomenon in cell biology is when a transcription factor promotes the expression of both another proteincoding gene and a miRNA that posttranscriptionally inhibits the target proteincoding gene. However, various com binations of mi RNAs, proteins and transcription factors can exist within feedforward loops. In lymphoma cells, miR1792 helps to sensitively calibrate the activity of the MYC oncogene by participating in a feed forward loop with MYC, serine/threonineprotein kinase Chk2 (CHEK2) and hu antigen R (HUR; also known as ELAV1) 17 (FIG. 1e) . miR1792 inhibits the activity of MYC through direct targeting of MYC transcripts as well as through inhibition of CHEK2. This allows the RNA binding protein HUR, normally repressed by CHEK2, to bind MYC transcripts and prevent their translation 17 . Without this mechanism to balance expression of MYC, which also participates in a positive feedback loop with the transcription factor E2F, it would rise unchecked to levels that promote apoptosis 17 . Nature Reviews | Cancer ncRNA genes can occupy multiple nodes One of the great challenges in understanding the func tion of ncRNAs in cancer is that ncRNAs do not always have a singular role in the process of tumorigenesis. An ncRNA may function as a tumour suppressor in one type of cancer but promote disease progression in another type 18 . In other cases, multiple species of gene products from the same ncRNA gene locus may operate synergistically or in opposition within a given pathway. The multifaceted functions of many ncRNA genes pro vide further evidence that the genome is not organized to contain individual genes with individual functions but instead is often highly multiplexed at particular loci to produce manifold gene products that allow for an array of possible finetuned responses to complex pathway stimuli.
ncRNAs with context-dependent roles
Even with the ability to computationally predict poten tial targets of certain species of ncRNAs, like mi RNAs
, it can be difficult to accurately predict their oncogenic or tumoursuppressive role in cancer. Part of the reason lies in the vast quantity and diversity of targets a given miRNA may have. Without knowing the func tion of each of the downstream targets, whether each is expressed and to what degree the miRNA inhibits the expression of each, it is difficult to predict the overall effect of the lossoffunction or gainoffunction of a miRNA on tumour growth. One reason for this challenge is that ncRNA interactions can be context dependent or celltypedependent (reviewed in REF. 18 ). Such is the case for miR125b, which acts as a tumour suppressor in some tumour types and as an oncogene in others 18 . Whereas the basic mechanisms by which miR125b functions remain the same across all tissues, the pool of miR125b targets that are expressed varies by cell type, allowing miR125b to target tumourpromoting tran scripts in cells of solid tumours and tumoursuppressive transcripts in cells of haematological cancers 18 . Members of the miR29 family of mi RNAs, consist ing of three isoforms (miR29a, miR29b and miR29c), have been reported to play dual roles: they can act as tumoursuppressor mi RNAs in mantlecell lymphoma, acute myeloid leukaemia (AML), lung cancer, diffuse large B cell lymphoma and Burkitt lymphoma 19, 20 and as oncogenic mi RNAs in indolent human B cell chronic lymphocytic leukaemia, AML and metastatic breast cancer 19 . A contextdependent dual role of another miRNA, miR375, has been observed in prostate cancer 21 . miR375 is highly expressed in an androgen dependent human prostate cancer cell line, 22Rv1. Inhibition of miR375 decreased the viability of 22Rv1 cells and derepressed the expression of the tumoursuppressor gene RB1. Very low expression of the same miRNA has been detected in the malignant androgenindependent prostate cancer cell line PC3 (REF. 21 ). Overexpression of miR375 in PC3 cells had antiproliferative effects and blocked the expression of one of its known targets, the gene cyclin D2 (CCND2) 21 . Additionally, the effects of miR191/425 cluster expression in breast cancer cell lines were found to be dependent on oestrogen receptor α (ERα; also known as ESR1) expression 22 . ERαpositive cells express high levels of the miR191/425 cluster, lead ing to the suppression of the tumoursuppressor gene early growth response 1 (EGR1). ERαnegative cells express low levels of the miR191/425 cluster. When both miR191 and miR425 were overexpressed in ERαnegative cells, tumour growth and metastasis were impaired 22 . The examples reported here indicate that the same miRNA can act as an oncogene or a tumour suppressor not only in different types of cancer, like miR125b and miR29b, but also within the same type of cancer, like miR375 and the miR191/425 cluster.
Supergenes
The ability of ncRNA genes to occupy multiple nodes in cancer networks can be manifested by the context dependent function of an individual gene product (as discussed above) as well as by the generation of diverse products from a single gene locus. The numer ous products may be the result of alternative spli cing, a common phenomenon during transcription in 136, 137 . In addition, The Cancer Genome Atlas (TCGA) 138 Tools for the bench. Identification of ncRNA signatures as prognostic and diagnostic biomarkers in human tumour samples is made through next-generation sequencing 146, 147 of ncRNAs. In addition, the photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) technique identifies interactions of ncRNA and coding RNA with proteins, such as the protein Argonaute 2 (AGO2); however, low-abundance targets may not be captured by this technique.
Another tool in the ncRNA field is a genomic editing tool called the CRISPR-Cas9 system 64, 148 . This system allows targeted editing of the genome, for example, to cleave part of the genome that carries mutations and successfully repair them. The CRISPRCas9 system is also used for ncRNA genomic deletions to study the functional roles of ncRNA in cancer.
In order to study phenotypic changes in human tumour cell lines and in mouse models, complementary antisense RNA or DNA oligonucleotides 149 are used that block the interaction between ncRNAs and their gene target as well as artificial decoying molecules 77 that inhibit mi RNAs through multiple complementary artificial binding sites cloned into and expressed from DNA plasmids 150 .
Tools for in vivo manipulation of ncRNA networks. Systemic delivery of synthetic miRNA 151 or long non-coding RNA inhibitors 152 in vivo without toxic collateral effects is still a major challenge. A paradigm for successful delivery of antisense RNA is the example involving the oncomiR miR-155. Anti-miR-155 was placed in nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) 153 as well as conjugated to a peptide with a low-pH-induced transmembrane structure (pHLIP) 154 and was successfully delivered, reduced the tumour growth in mice and did not induce toxicity in mice. Furthermore, antisense DNA oligonucleotides against metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) inhibited human lung cancer metastasis in mice xenografts 155 .
Supergene
A locus that produces multiple functional RNAs.
Endogenous small interfering RNAs
(Endo-siRNAs). Small RNAs that, unlike microRNAs, are derived from perfectly complementary senseantisense RNA hybrids (double-stranded RNA).
Mirtrons
MicroRNAs derived from short hairpin introns and processed by the splicing machinery but not by ribonuclease 3 (Drosha).
Pseudogene
A nucleotide sequence that resembles a gene but does not lead to any protein expression.
Nuclear paraspeckles
Nuclear domains within interchromatin spaces, enriched in RNA processing factors.
which certain exons are retained or lost, resulting in different endproduct proteins or ncRNAs 23 . In addi tion, some genetic loci concurrently encode multiple products, including mi RNAs, lncRNAs, circRNAs and proteins 24 . A 'supergene' yields more than one species of gene product either through the production of dis tinct transcripts for each product (type I supergenes) or through the production of a single transcript that is post transcriptionally processed to generate multiple func tional effectors (type II supergenes). Type III supergene loci are those that combine characteristics of both type I and type II supergenes. By supplying numerous prod ucts that occupy multiple nodes within a signalling path way, the high density of genetic information encoded at supergenes may provide builtin measures to buffer or finetune the effects downstream of transcription at the locus.
Type I supergenes. The activating signal cointegrator 1 complex subunit 3 (ASCC3) locus generates either a pro tein or a lncRNA to regulate cellular activity in response to ultraviolet radiation 25 . After DNA damage by ultra violet radiation or chemotherapeutic agents, it is crucial for the survival of cells not only to enact mechanisms to repair the damage but also to arrest processes that may exacerbate genome instability, such as transcrip tion 26 . ASCC3 is expressed under normal conditions and functions to maintain but not initiate global repression of transcription after DNA damage 25 . However, once DNA damage occurs and RNA synthesis is widely inhib ited, the ASCC3 locus stops producing proteincoding transcripts and instead generates a shorter ncRNA transcript 25 . This ncRNA form of ASCC3 functions to oppose the actions of the ASCC3 protein and aids in the recovery of global RNA synthesis 25 . By producing multiple gene products, the ASCC3 locus can participate in the signalling pathways that control cellular responses after DNA damage in a contextspecific and temporally appropriate way.
Type II supergenes. Small RNAs, such as mi RNAs, endogenous small interfering RNAs (endosiRNAs) and tRNAderived RNA fragments (tRFs), are not tran scribed directly in their mature form. It is possible that cells are incapable of specifically transcribing very short regions of the genome. Alternatively, the transcription of long RNA transcripts may provide evolutionary advan tages in the form of distinct opportunities for fine tuning the expression of shorter mature products through the regulation of processing steps. A third possibility is that the longer transcript possesses inherent functions dis tinct from its role as a precursor RNA and that both the longer and shorter RNA moieties are required for cellu lar functions. Such genes that encode multiple functional gene products within a single transcript can be classified as type II supergenes.
Some ncRNAs are produced from the transcripts of proteincoding genes. Though the host genes of some mi RNAs produce transcripts with no known function apart from being a miRNA precursor, many host genes for mi RNAs are proteincoding and produce products other than mi RNAs from the primary transcript. One of the first examples of this phenomenon was the dis covery that the gene encoding miR208a is located in the intron of the gene myosin heavy chain 6 (MYH6). The transcript produced from this locus generates both miR208a and the MYH6 protein, both of which help to coordinate cardiac contractility 27 . In cancer, the onco genic miRNA (oncomiR) miR483 is produced from the intron of the oncoproteincoding gene insulinlike growth factor 2 (IGF2) 28 . Other examples of ncRNAs produced from proteincoding transcripts include mirtrons 29 and circRNAs 30 . EndosiRNAs can also be generated from pseudogene transcripts. For example, endosiRNAs cleaved from nat urally occurring doublestranded RNA (dsRNA) have been identified in plants, C. elegans and mouse oocytes 31 .
The first observation of endosiRNAs in human cancer cells was the discovery of cleaved inhibitory prod ucts from a transcribed pseudogene antisense to the gene protein phosphatase, Mg 2+ /Mn 2+ dependent 1K (PPM1K) in human hepatocellular carcinoma (HCC) 32 . The doublestranded precursor of the cleaved endo siRNA is derived from either binding of the antisense pseudogene transcript to the sense transcript of PPM1K or the formation of internal hairpin structures within the pseudogene transcript 32 . The endosiRNAs were downregulated in HCC tumours compared with normal tissue, and functional testing showed that the PPM1K pseudogene-endosiRNA axis influenced the growth of tumour cells 32 . Taken together, these results suggest that loss of PPM1Kpseudogenederived endosiRNAs confers a growth advantage on cancer cells in HCC. Whether additional endosiRNAs generated from human pseudogenes exist and contribute to tumori genesis remains to be seen. Either result would have interesting implications not only for the functional rele vance of human pseudogenes but also for the evolution of cellular mechanisms to control gene expression.
The noncanonical 3ʹ end processing of a larger lncRNA to generate smaller tRNAlike molecules is also involved in tumorigenesis. One example is the highly abundant lncRNA metastasisassociated lung adeno carcinoma transcript 1 (MALAT1) initially transcribed by RNA polymerase II (RNA Pol II) as an approximately 7 kb polyadenylated RNA transcript 33 . The mature MALAT1 transcript, however, is not polyadenylated but contains a triplehelix structure at its 3ʹ end to protect the transcript from endonuclease activity 34, 35 . The con struction of the triplehelix structure requires the cleavage of 62 bp at the 3ʹ end by RNase P 34, 35 . Further processing of the cleaved small RNA moiety produces a tRNAlike molecule termed MALAT1associated small cytoplasmic RNA (mascRNA), which is efficiently shut tled to the cytoplasm, while mature MALAT1 is retained in the nucleus 33 . MALAT1 is known to be required for the retention of some polyadenylated RNA transcripts in the nucleus and proper localization of splicing factors to nuclear paraspeckles in the nucleus 36 . mascRNA is more highly conserved than MALAT1, and lossof function or gainoffunction experiments suggest that it plays an important role in monocyte-macrophage functions by influencing tumour necrosis factor (TNF) recep tor superfamily member 6 (TNFRSF6; also known as FAS), TNF ligand superfamily member 6 (TNFSF6; also known as FASLG), TNF, interleukin6 (IL6) and other chemokines 33, 37 . However, its molecular mechanism of action is not yet known.
Mature tRNA molecules themselves serve as precur sors for an abundant class of miRNAlike small ncRNA molecules, tRFs 38 (FIG. 2) . The 14to30nucleotide single stranded RNA moieties are cleaved from mature tRNAs through a not yet fully elucidated process (FIG. 2h; reviewed by Kumar et al. 39 ). Both the endoribonuclease Dicer 40, 41 and angiogenin have been shown to play a role in tRF biogenesis 42, 43 . Unlike mi RNAs, tRFs are restricted to the cytoplasm; however, tRFs bind to Argonaute pro teins and may regulate the abundance and translation of long RNAs in a miRNAlike manner 38, 44, 45 . The function of this class of small RNAs has been implicated in the pathogenesis of lymphoma 41, 45 , prostate cancer 46 and breast cancer 47 . Functioning through a competitive binding mechanism (discussed below) rather than an RNAinduced silencing complex (RISC)mediated mech anism, tRFs act as tumour suppressors in breast cancer by sequestering the RNAbinding protein nucleasesensitive elementbinding protein 1 (YBX1) and thus permitting the destabilization of oncogenic transcripts that would be stabilized by YBX1 binding 47 .
Type III supergenes. Some genetic loci produce multi ple gene products from distinct transcripts and multiple gene products from the same transcript. Such is the case for the H19, imprinted maternally expressed transcript (nonprotein coding) (H19) locus (FIG. 2a-g ). The H19 locus encodes the lncRNA H19 and miR675 (REF. 48) in one direction and the protein H19 opposite tumour suppressor (HOTS) and the lncRNA 91H in the opposite direction. Initially, H19 was thought to be a tumour sup pressor because transcription of H19 competes for tran scription factor binding with a nearby oncogene, IGF2 (REF. 49 ). However, further study revealed that though the act of H19 transcription is indeed tumour suppressive through reduction of IGF2 transcription, the lncRNA H19 itself promotes oncogenesis. Fulllength H19 regu lates the epigenetic state of several genetic loci, including that of other lncRNAs 50 . Direct binding and inhibition of the protein adenosylhomocysteinase (AHCY; also known as SAHH) by H19 indirectly inhibits DNA methyltrans ferase 3B (DNMT3B)dependent DNA methylation at these genetic loci, allowing spuri ous transcription in endometrial cancer cells 50 . H19, like other ncRNAs, tends to be expressed specifically in certain cancer types 51 , and different aspects of its function also seem to be restricted among certain cells within a hetero geneous tumour cell population 52 . The lncRNA H19 acts as a competi tive endogenous RNA (ceRNA), through sequestration and competitive binding of several tumoursuppressive mi RNAs, including let7, miR200b and miR200c. In doing so, H19 facilitates epithelial-mesenchymal tran sition and mesenchymal-epithelial transition during different stages of breast cancer metastasis 52, 53 . The other lncRNA encoded at this locus, 91H, is transcribed in the antisense direction to H19 and has also been shown to function in an oncogenic manner by promoting pro liferation, migration and invasion in colorectal cancer (CRC) cells, though its exact mechanism of action is not known 54 . The H19 locus also encodes a tumour suppressor, HOTS, which has been shown to inhibit the growth of rhabdomyosarcoma and choriocarcinoma cells 55 and suppress growth of cervical cancer tumours in mice 55 .
The fact that the functional H19 transcript encodes miR675 makes the H19 gene locus more complex than either a type I or type II supergene. miR675 (REF. 48 ), encoded in the first exon of H19 (FIG. 2c) , is a devel opmental regulator and tumour suppressor in pros tate cancer 56 , nonsmallcell lung cancer (NSCLC) 57 , breast cancer 58 and liver cancer 59 . Excision and matur ation of miR675 from H19 occurs through a typical pro cess mediated by ribonuclease 3 (Drosha) and Dicer 48 . During development, cells employ the RNAbinding protein HUR to inhibit processing of H19 by Drosha and allow cell proliferation 60 . Cancer cells may use the same process to promote cell proliferation in tumour types where HUR expression is high.
We speculate that as our understanding of the extent of multiple transcripts and functional RNAs produced from the same genetic locus improves, we may find that almost every gene has 'supergene' capabilities.
Other patterns of ncRNA networks Beyond canonical network motifs, other recurrent patterns of interactions have been identified in cancer networks involving ncRNA nodes. These patterns may represent novel motifs or interactions that overlap with canonical network motifs (FIG. 2i-j) .
Regulation of protein complexes
Protein coupling is a major means by which ncRNAs function in gene regulatory and cell signalling net works. ncRNAs can bind to individual proteins as well as complexes of proteins and regulate aspects of their function 61 . The direct binding of ncRNAs to proteins in some cases facilitates their ability to target specific pro teins and in other cases provides scaffolding for protein complexes to assemble.
Riboproteins. In eukaryotes, RNA cooperates with pro teins in functional units often termed riboproteins or ribonucleoproteins. A large number of cellular house keeping mechanisms rely on the interaction between RNAs and protein complexes. For example, the main tenance of telomeres is facilitated through the action of telomerase reverse transcriptase (TERT) and dyskerin pseudouridine synthase 1 (DKC1) using telomerase RNA as a template 62, 63 . The two subunits of eukary otic ribosomes are composed of four highly structured ncRNAs (18S, 5S, 28S and 5.8S) and over 75 proteins that work together to manufacture the protein products of the cell 63 . ncRNA guides. Some protein complexes draw upon ncRNAs as a source of specificity. For example, the prokaryotic defence mechanism against DNAbased viruses, CRISPR, which has been coopted as a powerful research tool, uses lncRNAs to guide Cas9 to specific DNA regions 64 . In addition, the proteins in RISC interact with various combinations of small ncRNAs to inhibit the expression of mRNAs. The sequence of the small ncRNA, usually a miRNA, determines which transcripts will be targeted by RISC. RISC represents a prominent example of protein complexes recruited by one RNA species to influence another. The detailed mechanisms of miRNAmediated silencing of mRNA transcripts have recently been reviewed elsewhere 65 . Nature Reviews | Cancer Recruitment of protein complexes. The discovery that the lncRNA HOX transcript antisense RNA (HOTAIR) alters targeting of the Polycomb repres sive complex 2 (PRC2) 66 first showed that ncRNAs can recruit chromatin modifying complexes to affect gene transcription. Here, lncRNAs act as address codes to direct PRC2 to specific sites for epigenetic silencing, redirecting its occupancy and leading to genomewide modification in DNA histone H3 lysine 27 methylation (H3K27me) that resemble epigenetic states found in early development 66 . Changes in the epigenetic state such as these in cancer cells lead to gene expression pat terns that support migration and invasion 66 . In addition to HOTAIR, other lncRNAs, such as neuroblastoma associated transcript 1 (NBAT1) and MIR31 host gene (MIR31HG), have been shown to interact with PRC2 to influence the epigenetic state of cancer cells 67, 68 . How lncRNAs initiate interaction with PRC2, what motifs are required for binding and whether these interactions are specific have not yet been resolved. Recent studies indicate that RNA recruitment of PRC2 may simultan eously be specific, as seen with RepA RNA, and pro miscuous, as seen with non relevant bacterial mRNA, but the in vivo relevance of this observation requires further investigation 69 . Targeting of other chromatinmodifying complexes often requires the function of ncRNAs. For example, the switch/sucrose nonfermentable (SWI/SNF) com plex, also known as BRG1 or HBRMassociated factors (BAF), is also regulated by ncRNAs. In prostate cancer, the lncRNA second chromosome locus associated with prostate 1 (SChLAP1) impairs the ability of the SWI/SNF chromatin remodelling complex subunit SNF5 to bind to the genome, resulting in genomewide aberrant gene expression and tumorigenesis 70 (FIG. 2i) . In addi tion, the expression of the Wntpathwayresponsive transcription factor 7 (TCF7) is partially upregulated in HCC through recruitment of the SWI/SNF complex by the lncRNA lncTCF7 (REF. 71 ). In addition, the function of DNA methylases sometimes requires ncRNAs. The lncRNA TCF21 antisense RNA inducing demethylation (TARID) enables transcription of the tumoursuppressor gene transcription factor 21 (TCF21) through recruit ment of the DNA demethylation regulator growth arrest and DNA damageinducible protein GADD45α 72 .
Control via competitive interactions
Another method by which ncRNAs contribute to gene regulatory networks is through physical interaction and sequestration of a target molecule, such as a miRNA or protein. The phenomenon, initially proposed in plant biology as the concept of 'target mimicry' (REF. 73 ) and frequently referred to in mammalian biology as 'spon ging' , prevents the target molecule from interacting with other binding partners 74 . Even though synthetic mol ecules to inhibit specific RNAs had been widely used before as research tools [75] [76] [77] , the discovery that endo genous mammalian RNAs could act as sponges showed that competitive binding by RNAs is a physiological con trol mechanism in mammalian regulatory networks 74 . Since then, cell fate decisions in both developmental as well as pathological cancer contexts have been shown to be influenced by regulation of cellular machinery through ceRNAs 74, 75, [78] [79] [80] [81] . Multiple species of RNAs have been proposed as possible ceRNAs, including mRNAs, lncRNAs, lncRNA pseudogenes, circRNAs and tRFs. Modulation of gene regulatory network interactions through competitive binding would require precise adjustment of molecule abundance to obtain the appropriate stoichiometry for effective competition 82, 83 . Using computational strat egies to integrate gene coexpression data, the pres ence and abundance of miRNA target sites, data from crosslinking immunoprecipitation followed by sequencing (CLIPseq) and the level of complementarity between RNAs, many researchers have developed models to predict ceRNA function in cells and databases to anno tate possible ceRNA interactions [84] [85] [86] [87] [88] [89] . In this section, we provide a few examples of how individual ncRNAs may participate as ceRNAs in regulatory networks in cancer. The ceRNA hypothesis has been thoughtfully and thoroughly reviewed elsewhere 74, 75, 90 along with an extending hypothesis that groups of RNAs with similar miRNA binding sites may prove more physiologically relevant as competitive effectors in cell biology than individual ceRNAs 75 .
Competing lncRNAs. Because of shared sequence homology with their parental genes, lncRNA pseudo genes represent a potential pool of ceRNA effectors. If abundant enough, pseudogenes that contain miRNA binding sites also shared with parental transcripts can increase the stability of the parental transcript by competing for inhibitory mi RNAs. Experiments in mice have shown the BRAF pseudogene (Braf trans forming gene, related sequence 1 (Braf-rs1) in mice; BRAF pseudogene 1 (BRAFP1) in humans) is capable imprinted maternally expressed transcript (non-protein coding) (H19) locus encodes genes in both directions -the long non-coding RNA (lncRNA) H19, the microRNA (miRNA) miR-675, the protein H19 opposite tumour suppressor (HOTS) and the lncRNA 91H -which are not only of different gene types but also have opposing roles in tumorigenesis. Thus, the entire locus has a dual and possibly context-dependent role. b | The transcription of H19 is a tumour-suppressive event because it competes for transcription factor binding with a nearby insulin-like growth factor 2 (IGF2) locus, thereby inhibiting oncogenic IGF2 expression. c | The lncRNA H19 is processed to produce miR-675, a miRNA that inhibits a number of oncogenic transcripts. d | The lncRNA H19 acts as a competitive endogenous RNA (ceRNA) that competitively binds tumour-suppressive mi RNAs. e | The lncRNA H19 binds to adenosylhomocysteinase (SAHH), which prevents it from facilitating DNA methylation through the action of DNA methyltransferase 3B (DMNT3B). The lack of methylation is associated with spurious transcription in cancer. f | The lncRNA transcribed antisense to H19, 91H, also promotes oncogenesis. g | HOTS functions as a tumour suppressor through unknown mechanisms. h | tRNAs serve as precursors for miRNA-like small RNAs (tRNA-derived RNA fragments (tRFs)). i | The lncRNA second chromosome locus associated with prostate 1 (SChLAP1) inhibits the activity of the switch/sucrose non-fermentable (SWI/SNF) complex in producing repressive chromatin modifications. j | The BRAF pseudogene 1 (BRAFP1) acts as a sponge to sequester mi RNAs that target BRAF. k | A lncRNA transcribed antisense to the gene encoding paxillin (PXN), PXN-antisense1 (PXN-AS1), binds the PXN transcript and inhibits miRNA binding. 3ʹUTR, 3ʹ untranslated region; ERH, enhancer of rudimentary homologue; ME, methylation; ncRNA, non-coding RNA; RNA Pol II, RNA polymerase II. 
Alu element
A short interspersed element, 300 bp in length, that is repeated in the human genome and forms a characteristic double-stranded RNA embedded in the precursor mRNA.
of sequestering mi RNAs that target both the BRAF pseudogene as well as BRAF (FIG. 2j) . Overexpression of Braf-rs1 in mice led to an increase in BRAF abun dance, activation of the ERK pathway and the develop ment of lymphoma 91 . Conversely, depletion of Braf-rs1 resulted in decreased expression of BRAF and reduced tumorigenesis 91 . It remains to be seen whether a ceRNA network in human cancers activates BRAF. However, BRAFP1 expression has been found in human cancer cell lines, and copy number amplification of the genomic region containing BRAFP1 has been observed in colon cancer patient tumour data sets 91 .
Decoy role of circRNAs.
A handful of circRNAs are deregulated in cancer (TABLE 1) , and some are capable of sequestering mi RNAs (FIG. 3) ,though their functional role is still under investigation. The first circRNA discovered to harbour complementary sequences for mi RNAs is the sexdetermining region of Chr Y (Sry) gene expressed in the mouse testis, which contains 16 binding sites for miR138 (REFS 92, 93) . In addition, the circular isoform of the coding gene itchy E3 ubiq uitin protein ligase (ITCH), circITCH, functions as a sponge for miR7, miR17 and miR214 in oesoph ageal squamous cell carcinoma (ESCC). CircITCH expression functions as a tumour suppressor in ESCC by sponging mi RNAs that would inhibit the produc tion of the ITCH protein that functions to inhibit the Wnt-βcatenin pathway 94 . The antisense cerebellar degenerationrelated pro tein 1 (CDR1as) contains 74 binding sites for miR7 and may negatively regulate miR7. Thus, CDR1as is also known as ciRS7. Direct interaction of ciRS7 and miR7 was experimentally demonstrated in human cell lines, as was their colocalization in human cell lines and in the mouse embryonic brain 93, 95 . The functional role of the sponging effect of ciRS7 on miR7 in cancer is now starting to be clarified. It is known that expression of the tumour suppressor miR7 is reduced in cancer stemlike cells 96 and furthermore inhibits the expression of onco genes, such as epidermal growth factor receptor (EGFR), insulin receptor substrate 1 (IRS1) and IRS2, involved in glioblastoma 97 . miR7 also targets the oncogenes EGFR and CRAF in CRC. ciRS7 expression levels are higher in CRC compared with normal tissues, and it is associ ated with poor patient survival. In CRC cell lines, ciRS7 sequesters miR7, and consequently the expression of its target oncogenes EGFR and CRAF increases. This find ing implies that ciRS7 could be used as a therapeutic target in CRC 98 . The circRNA of the transcription factor forkhead box protein O3 (circFoxo3) forms a ternary complex with two cell cycle regulatory proteins, the cyclin dependent kinase inhibitor p21 and cyclindependent kinase 2 (CDK2) 99 , and blocks cell cycle progression. The discov ery of the circFoxo3-p21-CDK2 complex 99 is the first indication that circRNAs can bind and perhaps sequester proteins in addition to mi RNAs. These unique proper ties of circRNAs suggest their promising application as therapeutic targets in cancer 100 .
Interactions between long RNAs
Another mechanism by which ncRNAs participate in gene regulatory networks is through direct binding of lncRNAs to other RNA molecules to regulate their sta bility or translation. These interactions rely on binding of the lncRNA to its RNA target and either creating a substrate for protein function or removing access for miRNA or inhibitory protein effectors.
A tumoursuppressor lncRNA that is directly induced by the tumour suppressor p53 (REF. 101 ), LincRNAp21, binds directly to at least two mRNAs, including JUNB, which encodes an AP1 transcription factor subunit and CTNNB1, which encodes βcatenin, to repress their translation 102 . This binding appears to be mediated by base pair interactions between com plementary sequences within LincRNAp21 and its target mRNAs 102 and leads to recruitment of negative regulators of translation such as the proteins prob able ATPdependent RNA helicase DDX6 and synaptic func tional regulator FMR1 102 . It is not known how many other mRNAs can be targeted by LincRNAp21. Also unknown is whether this mechanism of translational inhibition is widely relevant to the binding of other ncRNAs with mRNA transcripts. However, given the important tumoursuppressive role of LincRNAp21, further investigation into this mechanism may illuminate its role in lung cancer.
Staufen1-mediated mRNA decay (SMD) is a mech anism for proteinmediated degradation of mRNA, recognition of which occurs through lncRNAs. Specifically, most but not all mRNAs containing an Alu element in their 3ʹ untranslated region (3ʹUTR) are tar geted by SMD 103 . A subset of lncRNAs, categorized as halfStaufen1binding site RNAs (1/2sbsRNAs), bind to Alucontaining mRNAs at their 3ʹUTR. This binding occurs through imperfect base pairing between areas adjacent to and including the Alu element, thereby This circRNA is regulated by hypoxia, and its depletion by small interfering RNA inhibits angiogenic sprouting of endothelial cells. This suggests that cZNF292 has proangiogenic activities 162 circRNAs, circular RNAs; circ-Foxo3, circRNA of the transcription factor forkhead box protein O3; circHIPK3, circRNA of homeodomain-interacting protein kinase 3; circ-ITCH, circRNA of itchy E3 ubiquitin protein ligase; ciRS-7, circular RNA sponge for miR-7; f-circM9, fusion circular RNA of the oncogenes MLL and AF9 in acute myeloid leukaemia; cZNF292, circular RNA from the gene zinc-finger protein 292; p21, cyclin-dependent kinase inhibitor.
forming dsRNAbinding protein Staufen homologue 1 (STAU1)binding sites. STAU1 then binds and mediates degradation of the newly formed duplex 104 . Other ncRNAs have been found to inhibit the func tion of STAU1. For example, the small nucleolar RNA host gene 5 (SNHG5),which serves as a precursor for the small nucleolar RNAs U50 and U50ʹ, is localized in the cytoplasm and binds to the 3ʹUTRs of over 100 different Alucontaining transcripts. The SNHG5 pro tein competes with the mRNAdestabilizing STAU1 protein for binding to the 3ʹUTR of spermatogenesis associated serine rich 2 (SPATS2) transcripts, for exam ple, thereby promoting stability of the transcipts 105 . The mRNAs protected by SNHG5 produce proteins that engage in cell survival pathways and promote tumour growth in CRC 105 . In addition to creating recognition sites for degra dation proteins, lncRNAs can protect transcripts by making miRNA binding sites on mRNAs inaccessible. The lncRNA produced in antisense to the gene encod ing paxillin (PXN) performs this function specifically for its antisense mRNA 106 . Alternative splicing in HCC by the splicing factor muscleblindlike protein 3 (MBNL3) leads to the inclusion of an additional exon in the lncRNA. This exon contains a sequence complementary to the proteincoding mRNA for PXN. PXNantisense1 (PXNAS1) was shown to bind to the PXN mRNA and increase its stability by protecting it from miR24 and protein Argonaute 2 (AGO2) mediated degrada tion (FIG. 2k) . The resulting increase in PXN facilitates tumorigenesis in liver cells 106 .
Disruption of ncRNA networks in cancer
The networks in which ncRNAs perform their func tions serve to provide checks and balances on impor tant regu latory processes. Imbalances in the multiple layers of control of genes that allow the cell to repair DNA damage, organize chromatin, perform cell divi sion, respond to mitogenic signals and interact with other cell types could have detrimental consequences. Changes in these highly regulated pathways may lead to cell death or propel the cell towards uncontrolled cell growth and malignancy. In this section, we explore some of the known mechanisms by which ncRNA nodes of gene regulatory networks are corrupted in cancer
. Chemical modifications of RNA and epitranscriptomics have been recently reviewed 107, 108 and are not discussed in further detail here.
Remodelling of ncRNA networks
Tumorigenesis involves genomic alterations, such as chromosomal translocations, that cause a fusion between two genes that are otherwise located far from each other in the genome, resulting in a chimeric oncogene. This phenomenon may result in the fusion between two oncogenes. A recent study 109 investigated the impact that these genomic alterations may have on ncRNAs and specifically on circRNAs. Upon chromosomal trans location, two genes can bring complementary repetitive intronic sequences (Alu elements) together, favouring back splicing events that generate aberrant circRNAs, called fusion (f)circRNAs. Formation of fcircRNAs derived from recurrent chromosomal translocations of oncogenes may occur in liquid tumours such as in acute promyelo cytic leukaemia (APL) 110 and in AML 109 . The fusion of the two oncogenes promyelocytic leukae mia (PML) and retinoic acid receptor alpha (RARA) in APL gives rise to the fcircPR, while the fusion of lysine methyl transferase 2A (KMT2A; also known as MLL) and the super elongation complex subunit AF9 (also known as MLLT3) in AML produces fcircM9, and both circRNAs had proproliferative and pro tooncogenic activities in an immortalized mouse cell line 109 . The tumourpromoting property of fcircM9 was increased by the presence of the MLL-AF9 fusion pro tein in vitro and in vivo 109 . The formation of fcircRNAs was also examined in solid tumours such as in Ewing sarcoma and in lung cancer 109, 111 . The fusion between the genes encoding EWS RNAbinding protein 1 (EWSR1) and the ETS transcription factor FLI1 in Ewing sar coma and echinoderm microtubule associ ated protein like 4 (EML4) and activin A receptor like type 1 (ALK1; also known as ACVRL1) in lung cancer produced Nature Reviews | Cancer because it alleviates expression of oncogenic targets. In an opposite manner, circRNA may exert an antitumoural effect when it sponges mi RNAs that suppress tumour-suppressor genes (oncogenic miRNAs, oncomiRs); for example, circ-ITCH decoys miR-7, miR-17 and miR-214 and liberates the tumour-suppressor gene itchy E3 ubiquitin protein ligase (ITCH).
Alternative polyadenylation signals
When more than one site within a gene locus codes for the signal that allows a string of adenosine bases (poly(A) tail) to be added to the end of the transcript.
fcircEF1 and fcircEA1, respectively 109 . The relevance of these findings may be considered important, as it was estimated that almost 50% of aberrant transloca tions observed in various types of cancer may generate fcircRNAs. Nevertheless, the oncogenic potential of other fcircRNAs needs further investigation.
Altered targeting by ncRNA
Altered adenosine-to-inosine editing reprogrammes miRNA targeting. A major cellular housekeeping pro cess is the posttranscriptional converting or editing of adenosine to inosine (AtoI) in transcripts, catalysed by three enzymes belonging to the family of dsRNA specific adenosine deaminases (ADAR1, ADAR2 and ADAR3). These three enzymes have common func tional domains but they differ in their AtoI editing activity 112 . This process may occur in coding regions, although it is more frequent in noncoding regions such as introns and 3ʹUTRs where inverted Alu repeats form dsRNA structures 113, 114 . By allowing the formation of new inosine-cytosine base pairings 115 , it has been hypothesized that AtoI editing can alter the structure of transcripts 116 (FIG. 4) .
Recent bioinformatic comparison of AtoI editing in tumours to normal tissue across 14 types of cancer found that whereas overall AtoI editing remains largely unchanged in cancerous tissues, there was an increase or decrease in editing sites in the 3ʹUTRs of cancerassociated genes, particularly in miRNA binding sites 117 , which could either lead to the loss or gain of miRNA binding sites and was found to be highly con textspecific. Upregulation or downregulation of AtoI editing was dependent on the tumour type and the type of tumorigenic drivers 117 . Results from this study 117 suggest that changes to the AtoI editing pro cess could drastically reshape miRNA nodes in ncRNA networks by changing the pool of possible miRNA tar gets such as oncogenes or tumoursuppressor genes, thereby presenting a potential selective advantage for cancer cells.
AtoI RNA editing enzymes regulate not only miRNA targets but also miRNA precursors. ADAR enzymes form a heterodimer complex with Dicer to pro mote miRNA processing 118 or inhibit the micro processor complex cleavage of primary mi RNAs to suppress miRNA maturation 112 . In cancer, loss or gain of ADAR activity influences the expression of oncogenic and tumoursuppressive mi RNAs. In glioblastomas, AtoI editing within mi RNAs is decreased owing to impaired activity of ADAR2 compared with normal brain tis sue 119 . In melanoma, low expression of ADAR1 leads to decreased AtoI editing of miR4555p, resulting in a change in specificity and the targeting of different tran scripts compared with normally edited miR4555p 120 . This change contributes to the metastatic ability of melanoma 120 . Amplification of ADAR1 in NSCLC cell lines leads to increased levels of defective transcripts of neilike DNA glycosylase 1 (NEIL1), a DNA repair gene, and also increased levels of AtoI editing of miR138, an miRNA involved in chemoresistance and in cancer related pathways. The increased editing of NEIL1 and miR-138 transcripts led to increased growth of the NSCLC cell line A459. The high copy number of ADAR1 was also associated with poor prognosis in patients with earlystage lung cancer 121 . Moreover, increased catalytic activity of ADAR1 in leukaemic stem cells inhibits biogenesis of the tumour suppressor let7 family of mi RNAs and promotes leu kaemia stem cell self renewal 122 . Small molecule target ing of ADAR editase activity appears to restore let7 bio genesis and impede leukaemia stem cell renewal 123 . Given the role of ADAR enzymes in rewiring the cir cuitry of miRNA networks in cancer, the ADAR enzymes themselves may provide useful targets for therapeutic intervention.
3ʹUTR variations in cancer alter miRNA targeting in ncRNA networks. The 3ʹUTR of RNA, defined as the sequence between the stop codon and the poly(A) tail, contains a multitude of regulatory sequences for the maturation, localization, stability and translation of the RNA. More than 70% of mammalian genes contain alternative polyadenylation signals in the 3ʹUTR, which allow the formation of isoforms with multiple 3ʹUTRs derived from a single gene 124 . Although the ability to produce alternative 'switches' for the same transcript may allow finetuned differential expression of certain genes in a tissuespecific manner 125 , this system can be coopted in cancer cells to promote expression of onco genic signals. Indeed, one study found that cancer cells Non-coding RNAs (ncRNAs) routinely interact with proteins to coordinate the epigenetic marks to restrict transcription to a specific set of genes. Indeed, alterations to RNAs that participate in this process will transform the transcriptome and contribute to pathology. In addition, modifications to epigenetic marks of ncRNAs govern the actions of other nodes in ncRNA pathways, such as microRNA (miRNA) targeting of transcripts or long ncRNAs (lncRNAs) participating in competitive endogenous RNA (ceRNA) networks, have the potential to alter expression of these ncRNA effectors and disrupt their downstream targets, leading to dramatic changes in cell fate.
Numerous examples of aberrantly high or low expression of ncRNAs contributing to diseases have been studied. For example, hypermethylation of the tumour suppressor TP53-induced lncRNA TP53TG1 in cancer leads to decreased expression of TP53TG1 and promotes chemoresistance 156 . TP53TG1 regulates the subcellular localization of nuclease-sensitive element-binding protein 1 (YBX1). Loss of TP53TG1 in cancer allows YBX1 to accumulate in the nucleus and facilitate the expression of genes promoting cell growth 156 . A profile of the CpG island methylation status of transcribed ultra-conserved regions (T-UCRs) in eight different types of cancer cell lines demonstrated that T-UCRs are highly methylated 157 . When one of these T-UCRs, Uc.283+A, was overexpressed in a hypermethylated colon cancer cell line, the number of dead cells was increased, suggesting that T-UCRs have a growth inhibitory effect in colon cancer. In human colon cancer, melanoma and head and neck cancer, the mi RNAs miR-34b, miR-34c, miR-148 and miR-9 were found to be hypermethylated, resulting in increased expression of their targets MYC and cyclin-dependent kinase 6 (CDK6)
158
. Epigenetic loss of miR-124a has been reported in different human cell lines and primary tumours. Treatment of a human colon cancer cell line with a DNAdemethylating drug restored expression of miR-124a, leading to suppression of its target, the oncogene CDK6, and induction of the activity of the tumour suppressor RB1 159 . The finding that the methylation status of miRNA loci correlates with chemosensitivity suggests that epigenetic profiling of ncRNA loci could serve to identify biomarkers 160 and that DNA-demethylating drugs could be promising in ncRNA-based cancer therapies.
exhibit global shortening of 3ʹUTRs compared with normal cells, leading to the loss of miRNA and protein binding sites in 3ʹUTRs of oncogenic transcripts 126 . Cis-regulatory sequences in the 3ʹUTR are also sus ceptible to single nucleotide polymorphisms (SNPs), which occur frequently in the human genome in approximately every hundred base pairs 127 . Many silent polymorphisms, which do not alter coding sequences, may not in fact be silent. Those located in noncoding genomic regions have the potential to disrupt RNA-RNA or RNA-protein interactions in gene regulatory networks in cancer. A genomewide DNA sequen cing analysis of tumour tissues uncovered 12 SNPs in miRNA binding sites associated with human cancer 128 .
In lung cancer, a germline SNP in the 3ʹUTR of KRAS abrogated the binding site of let7, thus increas ing KRAS levels to promote tumour progression 129 . Moreover, a somatic SNP was found in the 3ʹUTR of the oncogene Mdm4, which inhibits the tumour sup pressor p53, that created a new binding site for miR191 (REF. 130 ). Recently, a study dissecting the KRAS 3ʹUTR in HeLa cells identi fied two 49nucleotide cis-regula tory sequences 131 containing a miR185 binding site and a stabilizing element. Knockdown of HUR and Dicer increased mRNA and protein levels of KRAS, indicat ing that mi RNAs and HUR cooperatively bind the same sequence in the 3ʹUTR of this oncogene and repress its expression. Moreover, the same repressive 49nucleotide sequence contains a SNP at the first nucleotide of a predicted miR185 target site, but its role has yet to be determined in cancer progression 131 . Variations in noncoding sequences also have the potential to create novel regulatory sequences that may be selected in cancer cells. One such example is a SNP in LINC00673, which establishes a binding site for miR1231. Subsequent downregulation of LINC00673 releases its target tyrosineprotein phosphatase non receptor type 11 (PTPN11) from ubiquitinmediated degradation. Increased PTPN11 leads to increased SRC-ERK oncogenic signalling and has been shown to be a risk factor for pancreatic cancer 132 .
Perspectives
What has become apparent, even from our incomplete understanding of the molecular processes through which ncRNAs contribute to cellular activity, is that ncRNAs participate extensively in gene regulatory net works. Rather than acting as a single link in a chain of cellular events, many but not all ncRNAs operate as a branch point with broadreaching outputs capable of transforming the transcriptome and proteome of cells to define cell fates. That a substantial proportion of these pleiotropic ncRNAs in turn regulate other pleiotropic ncRNAs adds exponential depth to the complexity of regulatory networks encompassing the genome.
The framework of network science provides some level of clarity to the complex nature of ncRNAs in cel lular pathways by facilitating the identification of recur rent patterns of interactions between ncRNA nodes and other pathway members. The study of transcriptional networks in bacteria has shown that the structure of net work motifs also correlates with the kinetics, sensitivity and robustness of network responses to perturbations 13 . For example, certain network motif configurations allow for either immediate or delayed response to the applica tion of a certain stimulus. Whereas many of these tem poral aspects of network motifs were deciphered using protein networks, it is not yet clear if ncRNA nodes in biological networks would yield similar kinetics. These aspects of ncRNA network biology remain to be studied.
In this new era, when assays to investigate the DNA sequence, chromatin modifications, gene expression and protein abundance in cells at a genomewide scale have become routine practice at the bench, the opportunity to deconvolute such complex networks is within reach. Particularly important in the design of effective cancer treatments, where singleagent targeted therapy has sometimes proved insufficient [133] [134] [135] , is a comprehensive understanding of the possible feedback loops, offtarget effects and modes of resistance to therapeutic manipu lation. A great deal of work remains to characterize the complex ncRNA networks that contribute to tumori genesis, but continued effort has the potential to better inform the selection of therapeutic targets. Technical tools to identify and experimentally validate many bio informatically predicted interactions within a ncRNAcoding RNA circuitry exist, are improving and have the potential to transform our understanding and treatment of diseases like cancer. The adenosine-to-inosine (A-to-I) RNA editing mechanism may generate transcriptome diversity by influencing both tumour suppressors and oncogenes.
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As shown here, double-stranded RNA-specific adenosine deaminases (ADARs) may change adenosine bases in Alu sequences to inosine in the 3ʹ untranslated region (3ʹUTR) of a tumour-suppressor gene. This process sometimes results in a loss or gain of microRNA (miRNA) binding sites. By contrast, ADARs may also positively regulate oncogene expression through A-to-I editing, thus drastically reshaping miRNA nodes in non-coding RNA networks by changing the pool of possible miRNA targets genes involved in carcinogenesis. The editing dysregulation by aberrant expression of ADARs is also a frequent characteristic of cancers. The involvement of this RNA editing mechanism in cancer development seems important for tumour progression. OncomiR, oncogenic miRNA.
